Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant
Peijia Medical was founded in 2012 and its headquarter is based in Suzhou, Jiangsu Province, China. It was listed on the Hong Kong Stock Exchange in May 2020. With "Devotion to the Heart, Reverence for Life" as its vision, Peijia Medical always puts life and safety in the first place, striving to maintain human life and health from its years of exploration in technology and its innovative persistence. Peijia Medical's strategic layout can be summarized as the "Innovation-oriented, Simultaneous Treatment of Cardiovascular and Cerebrovascular Diseases". It is dedicated to the innovation, R&D and production of high-end medical devices for structural heart disease and cerebrovascular interventions--covering aortic valve, mitral valve, tricuspid valve, surgical accessories, and diseases related to hemorrhage, ischemia and pathways in cerebrovascular intervention. It has built a relatively comprehensive array of product and solution portfolios in the field of structural heart disease and cerebrovascular interventions for use throughout China.
- Dr. Kar currently serves as the Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Health System, and Professor of Medicine at the David Geffen School of Medicine at UCLA.
- He is recognized as the leading physician in developing and implementing minimally-invasive techniques in structural heart disease interventions.
- Dr. Kar receives research grants from and is a consultant to multinational companies, such as Boston Scientific Corporation, Gore & Associates, and Abbott Vascular.
- Peijia Medical was founded in 2012 and its headquarter is based in Suzhou,Jiangsu Province,China.